Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.25 -1.2%	$3.66	$1.24 ▼ $4.08	$872.33M	0.96	3.95 million shs	3.70 million shs
CRON Cronos Group	$2.37 -6.0%	$2.06	$1.60 ▼ $2.77	$907.80M	1.01	2.70 million shs	2.67 million shs
PHAR Pharming Group	$11.65 +2.4%	$10.87	$6.73 ▼ $17.08	$779.70M	0.02	10,849 shs	2,998 shs
PRQR ProQR Therapeutics	$2.05 +1.5%	$2.10	$1.07 ▼ $4.62	$212.53M	0.43	254,268 shs	124,827 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-1.22%	-4.97%	-16.67%	+24.52%	+140.74%
CRON Cronos Group	-5.95%	+3.04%	+17.91%	+10.75%	+0.85%
PHAR Pharming Group	+2.37%	-11.94%	+17.09%	+23.53%	+49.17%
PRQR ProQR Therapeutics	+1.49%	-5.53%	-12.77%	+26.54%	-8.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	4.0763 of 5 stars	3.6	2.0	4.0	3.2	0.8	0.6
CRON Cronos Group	1.0916 of 5 stars	0.0	3.0	0.0	3.3	0.0	1.3
PHAR Pharming Group	2.1326 of 5 stars	3.5	3.0	0.0	1.9	0.0	0.6
PRQR ProQR Therapeutics	2.3216 of 5 stars	3.6	5.0	0.0	1.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	107.69% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
PHAR Pharming Group	3.00	Buy	$30.00	157.51% Upside
PRQR ProQR Therapeutics	3.13	Buy	$8.00	290.24% Upside

Current Analyst Ratings Breakdown

Latest PRQR, AKBA, PHAR, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/11/2025	PRQR ProQR Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/27/2025	PRQR ProQR Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00
6/27/2025	PRQR ProQR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$8.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$203.73M	4.23	N/A	N/A	$0.11 per share	29.55
CRON Cronos Group	$130.28M	6.97	$0.00 per share	5,415.63	$2.95 per share	0.80
PHAR Pharming Group	$297.20M	2.69	$0.08 per share	153.52	$3.50 per share	3.33
PRQR ProQR Therapeutics	$20.46M	10.54	N/A	N/A	$0.72 per share	2.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	N/A
CRON Cronos Group	$41.08M	$0.05	47.40	79.00	N/A	14.19%	-3.78%	-3.62%	N/A
PHAR Pharming Group	-$11.84M	-$0.13	N/A	388.33	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
PRQR ProQR Therapeutics	-$30.04M	-$0.46	N/A	N/A	N/A	-238.52%	-61.25%	-28.13%	N/A

Latest PRQR, AKBA, PHAR, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/7/2025	Q2 2025	PRQR ProQR Therapeutics	-$0.08	-$0.14	-$0.06	-$0.14	$5.01 million	$4.33 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.61	1.98	1.84
CRON Cronos Group	N/A	24.65	23.53
PHAR Pharming Group	0.38	2.79	2.07
PRQR ProQR Therapeutics	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CRON Cronos Group	8.71%
PHAR Pharming Group	0.03%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
CRON Cronos Group	7.30%
PHAR Pharming Group	2.07%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	265.15 million	257.19 million	Optionable
CRON Cronos Group	450	383.04 million	355.79 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
PRQR ProQR Therapeutics	180	105.21 million	96.38 million	Optionable

PRQR, AKBA, PHAR, and CRON Headlines

Recent News About These Companies

PRQR | ProQR Therapeutics N.V. Stock Price & News - WSJ

August 12, 2025 | wsj.com

ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital

August 9, 2025 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Passes Above 50-Day Moving Average - What's Next?

August 8, 2025 | marketbeat.com

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 7, 2025 | globenewswire.com

ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Monaco Asset Management SAM Increases Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

July 30, 2025 | marketbeat.com

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

ProQR Therapeutics price target raised to $5 from $4 at Evercore ISI

July 12, 2025 | msn.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com

July 8, 2025 | investing.com

PRQR - ProQR Therapeutics NV Sustainability - Morningstar

July 3, 2025 | morningstar.comM

PRQR - ProQR Therapeutics NV Key Metrics - Morningstar

July 2, 2025 | morningstar.comM

ProQR Therapeutics NV (PRQR) Stock Forums - Investing.com

June 29, 2025 | investing.com

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

ProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 27, 2025 | finanznachrichten.de

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

June 26, 2025 | globenewswire.com

ProQR Therapeutics Reports Q1 2025 Financial Results

June 2, 2025 | tipranks.com

ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year

May 24, 2025 | investing.com

ProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock News

May 13, 2025 | gurufocus.com

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

May 12, 2025 | globenewswire.com

ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position

May 10, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRQR, AKBA, PHAR, and CRON Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.25 -0.04 (-1.22%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.22 -0.03 (-0.92%)

As of 08/15/2025 08:00 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Cronos Group NASDAQ:CRON

$2.37 -0.15 (-5.95%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.38 +0.01 (+0.63%)

As of 08/15/2025 07:55 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Pharming Group NASDAQ:PHAR

$11.65 +0.27 (+2.37%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$11.70 +0.04 (+0.39%)

As of 08/15/2025 05:26 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NASDAQ:PRQR

$2.05 +0.03 (+1.49%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.04 0.00 (-0.24%)

As of 08/15/2025 04:10 PM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time